post image

Mergers & Acquisition - Companies working on Deuterated Drugs


Deuterated medication mergers and acquisitions (M&A) have been a major trend in the pharmaceutical sector in recent years. Some of the trends in Mergers & Acquisitions of companies working in deuterated drug discovery

Strategic Partnerships : Pharmaceutical companies are increasingly entering into partnerships or acquiring biotech firms specializing in deuterated drug development. This strategy allows them to access novel technologies and intellectual property related to deuteration.

Pipeline Expansion : Acquiring companies often seek to expand their drug pipelines with promising deuterated drug candidates. These candidates may offer differentiated therapeutic benefits over existing drugs or treat conditions where traditional formulations have limitations.

Market Potential : Deuterated drugs have the potential to address unmet medical needs or improve upon existing therapies. This market potential drives M&A activities as companies strive to capitalize on innovative treatments.

Technological Expertise : Companies involved in M&A transactions may gain access to specialized expertise in deuteration chemistry, formulation development, or preclinical and clinical research methodologies specific to deuterated drugs.

M&A Deuterated Drugs

Parent Company Acquired by Molecule Therapeutic Indication M&A Value
Auspex [2015] Teva Austedo (deutetrabenazine) Huntington's disease $ 3.5Bn
Avanir [2014] Otsuka Pharmaceutical AVP-786 Agitation in Alzheimer's disease $ 3.5Bn
Concert Pharmaceuticals [2021] Vertex CTP-656 VX-561 Cystic fibrosis $ 160Mn
DeuteRx [2018] Poxel DRX-065 NASH $ 8Mn in cash/ $ 1.29Mn shares
Vertex [2017] Merck KGaA M9831 Anti-cancer drug $ 230Mn
Concert [2023] Sun Pharma Deuruxolitinib Severe Alopecia Areata $576Mn

Share: